The FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
The FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
美國食品藥品管理局已批准Can-Fite Biopharma正在進行的2B期研究的Namodenoson治療代謝功能障礙相關脂肪肝炎（也稱爲非酒精性脂肪性肝炎）的新藥研究許可
The FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
美國食品藥品管理局已批准Can-Fite Biopharma正在進行的2B期研究的Namodenoson治療代謝功能障礙相關脂肪肝炎（也稱爲非酒精性脂肪性肝炎）的新藥研究許可
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。